Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZINGO

« Back to Dashboard

Zingo is a drug marketed by Powder Pharms and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.

The generic ingredient in ZINGO is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

Summary for Tradename: ZINGO

Patents:5
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: ZINGO

Ingredient-typeAmides
Drug ClassAmide Local Anesthetic
Antiarrhythmic
Physiological EffectLocal Anesthesia

Clinical Trials for: ZINGO

Tumescent Lidocaine Maximum Safe mg/kg Dosage
Status: Enrolling by invitation Condition: Anesthesia

Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients
Status: Recruiting Condition: Chronic Pain

Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving
Status: Recruiting Condition: Cocaine Addiction

Lidocaine: Effect of Lidocaine in Chronic Cough
Status: Completed Condition: Chronic Cough

Subcutaneous Lidocaine For Cancer-Related Pain
Status: Recruiting Condition: Cancer-related Pain

Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
Status: Completed Condition: Unstable Angina; Coronary Artery Bypass Graft; Dexmedetomidine; Lidocaine; Myocardial Injury; Arrhythmia; Blood Electrolyte Balance

Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization
Status: Recruiting Condition: Uterine Leiomyomas

Effect of Intravenous Lidocaine and Dexamethasone Combination on Postoperative Sore Throat, Cough and Hoarseness.
Status: Recruiting Condition: Postoperative Sore Throat, Cough, Hoarseness

A Dose-response Study of Lidocaine and Etomidate
Status: Completed Condition: Etomidate Overdose of Undetermined Intent

Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy
Status: Completed Condition: Pain, Postoperative; Analgesic Requirement; Stress Response; Return of Bowel Activity; Inadequate or Impaired Respiratory Function

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114Aug 16, 2007RXNo5,899,880<disabled>Y<disabled>
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114Aug 16, 2007RXNo8,540,665<disabled><disabled>
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114Aug 16, 2007RXNo6,004,286<disabled>Y<disabled>
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114Aug 16, 2007RXNo5,630,796<disabled><disabled>
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114Aug 16, 2007RXNo6,881,200<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc